Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Common Equity (2020 - 2025)

Core Scientific's Common Equity history spans 6 years, with the latest figure at -$1.3 billion for Q3 2025.

  • For Q3 2025, Common Equity fell 51.53% year-over-year to -$1.3 billion; the TTM value through Sep 2025 reached -$1.3 billion, down 51.53%, while the annual FY2024 figure was -$943.0 million, 57.98% down from the prior year.
  • Common Equity for Q3 2025 was -$1.3 billion at Core Scientific, down from -$1.2 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.3 billion in Q4 2021 and bottomed at -$1.3 billion in Q3 2025.
  • The 5-year median for Common Equity is -$392.4 million (2023), against an average of -$270.4 million.
  • The largest annual shift saw Common Equity soared 1403.19% in 2021 before it tumbled 673.39% in 2023.
  • A 5-year view of Common Equity shows it stood at $1.3 billion in 2021, then plummeted by 130.52% to -$409.3 million in 2022, then crashed by 45.83% to -$596.9 million in 2023, then crashed by 57.98% to -$943.0 million in 2024, then tumbled by 32.83% to -$1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Common Equity are -$1.3 billion (Q3 2025), -$1.2 billion (Q2 2025), and -$308.8 million (Q1 2025).